Know Cancer

or
forgot password

Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy


N/A
18 Years
N/A
Not Enrolling
Both
Curatively Resected Stage III Colon Cancer

Thank you

Trial Information

Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy


To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in
colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in
EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA
isolation kit, and SNP polymorphisms will be evaluated.


Inclusion Criteria:



- aged 18 or older

- curatively resected colon adenocarcinoma

- pathologically staged III

- adequate performance status

- adequate major organ functions

- to be treated with adjuvant FOLFOX chemotherapy

- written informed consent

Exclusion Criteria:

- those who disagree the study

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

neuropathy

Outcome Time Frame:

six months

Safety Issue:

Yes

Principal Investigator

Se Hoon Park, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Samsung Medical Center, Seoul, Korea

Authority:

South Korea: Korea Food and Drug Administration (KFDA)

Study ID:

2008-05-052

NCT ID:

NCT00977717

Start Date:

September 2008

Completion Date:

April 2010

Related Keywords:

  • Curatively Resected Stage III Colon Cancer
  • oxaliplatin
  • neuropathy
  • SNPs
  • Colonic Neoplasms

Name

Location